HIV/AIDS Therapy: Arginine 332 removal allows human TRIM5α to bind HIV capsids and restrict infection

AIDSWEEKLY Plus; Monday, September 4, 2006
Staff Medical Writers

According to a recently published report from the United States, "Human TRIM5α (TRIM5α(hu)) only modestly inhibits human immunodeficiency virus type 1 (HIV-1) and does not inhibit simian immunodeficiency virus (SIVmac).

"Alteration of arginine 332 in the TRIM5α(hu) B30.2 domain to proline, the residue found in rhesus monkey TRIM5α, has been shown to create a potent restricting factor for both HIV-1 and SIVmac."

"Here we demonstrate that the potentiation of HIV-1 inhibition results from the removal of a positively charged residue at position 332 of TRIM5α(hu)," Y. Li and colleagues at Harvard University reported.

"The increase in restricting activity correlated with an increase in the ability of TRIMS', mutants lacking arginine 332 to bind HIV-1 capsid complexes. A change in the cyclophilin A-binding loop of the HIV-1 capsid decreased TRIM5α(hu).

"R332P binding and allowed escape from restriction. The ability of TRIM5α(hu) to restrict SIVmac could be disrupted by the presence of any charged residue at position 332. Thus, charged residues in the v1 region of the TRIM5α(hu) B30.2 domain can modulate capsid binding and restriction potency," investigators said.

Li concluded, "Therapeutic strategies designed to neutralize arginine 332 of TRIM5α(hu) might potentiate the innate resistance of human cells to HIV-1 infection."

Li and colleagues published their study in the Journal of Virology (Removal of arginine 332 allows human TRIM5α to bind human immunodeficiency virus capsids and to restrict infection. J Virol. 2006 Jul;80(14):6738-44).

For additional information, contact J. Sodroski, Harvard University, School Medical, Dana Farber Cancer Institute, Dept. of Cancer Immunology & AIDS, 44 Binney St., JFB 824, Boston, MA 02115, USA.

The publisher of the Journal of Virology can be contacted at: American Society Microbiology, 1752 N St. NW, Washington, DC 20036-2904, USA.

Keywords: Boston, Massachusetts, United States, HIV/AIDS, Innate Resistance, Arginine 332, TRIM55 Alpha, Viral Capsid.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Li Y, Li X, Stremlau M, et al;, “Removal of arginine 332 allows human TRIM5α to bind human immunodeficiency virus capsids and to restrict infection”, J Virol. 2006 Jul;80(14):6738-44.

PubMED Related articles Search

2006-09-04
AW060902

Copyright © 2006 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.